Nature Communications (Sep 2023)

Human OPRM1 and murine Oprm1 promoter driven viral constructs for genetic access to μ-opioidergic cell types

  • Gregory J. Salimando,
  • Sébastien Tremblay,
  • Blake A. Kimmey,
  • Jia Li,
  • Sophie A. Rogers,
  • Jessica A. Wojick,
  • Nora M. McCall,
  • Lisa M. Wooldridge,
  • Amrith Rodrigues,
  • Tito Borner,
  • Kristin L. Gardiner,
  • Selwyn S. Jayakar,
  • Ilyas Singeç,
  • Clifford J. Woolf,
  • Matthew R. Hayes,
  • Bart C. De Jonghe,
  • F. Christian Bennett,
  • Mariko L. Bennett,
  • Julie A. Blendy,
  • Michael L. Platt,
  • Kate Townsend Creasy,
  • William R. Renthal,
  • Charu Ramakrishnan,
  • Karl Deisseroth,
  • Gregory Corder

DOI
https://doi.org/10.1038/s41467-023-41407-2
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 24

Abstract

Read online

Abstract With concurrent global epidemics of chronic pain and opioid use disorders, there is a critical need to identify, target and manipulate specific cell populations expressing the mu-opioid receptor (MOR). However, available tools and transgenic models for gaining long-term genetic access to MOR+ neural cell types and circuits involved in modulating pain, analgesia and addiction across species are limited. To address this, we developed a catalog of MOR promoter (MORp) based constructs packaged into adeno-associated viral vectors that drive transgene expression in MOR+ cells. MORp constructs designed from promoter regions upstream of the mouse Oprm1 gene (mMORp) were validated for transduction efficiency and selectivity in endogenous MOR+ neurons in the brain, spinal cord, and periphery of mice, with additional studies revealing robust expression in rats, shrews, and human induced pluripotent stem cell (iPSC)-derived nociceptors. The use of mMORp for in vivo fiber photometry, behavioral chemogenetics, and intersectional genetic strategies is also demonstrated. Lastly, a human designed MORp (hMORp) efficiently transduced macaque cortical OPRM1+ cells. Together, our MORp toolkit provides researchers cell type specific genetic access to target and functionally manipulate mu-opioidergic neurons across a range of vertebrate species and translational models for pain, addiction, and neuropsychiatric disorders.